Improved Risk Prediction in DLBCL By Combining Clinical and PET Features with Interim PET Assessment

被引：0

作者：

Hanoun, Christine ^{[1
]}

Heymans, Martijn ^{[2
]}

Wiegers, Sanne ^{[3
]}

Bes, Annelies ^{[4
]}

Duehrsen, Ulrich ^{[5
]}

Huettmann, Andreas ^{[1
]}

Kurch, Lars ^{[6
]}

Barrington, Sally F. ^{[7
,8
]}

Mikhaeel, George ^{[9
,10
]}

Lugtenburg, Pieternella ^{[11
]}

Ceriani, Luca ^{[12
]}

Zucca, Emanuele ^{[13
,14
]}

Gyorke, Tamas ^{[15
]}

Czibor, Sandor ^{[16
]}

Zwezerijnen, Gerben ^{[17
]}

Boellaard, Ronald ^{[18
]}

Zijlstra, Josee M. ^{[19
]}

Eertink, Corinne ^{[20
]}

机构：

[1] Uniklinikum Essen, Hematol, Essen, Germany

[2] Amsterdam UMC, Locat Vumc, Amsterdam, Netherlands

[3] Vrije Univ Amsterdam, Amsterdam UMC, Dept Hematol, Canc Ce, Amsterdam, Netherlands

[4] Amsterdam UMC, Hematol, Amsterdam, Netherlands

[5] Univ Klinikum Essen, Essen, Germany

[6] Univ Hosp Leipzig, Leipzig, Germany

[7] Kings Coll London, Sch Biomed Engn & Imaging Sci, London, England

[8] Guys & St Thomas PET Ctr, London, England

[9] Guys & St Thomas NHS Trust, Guys Canc Ctr, London, England

[10] Kings Coll Univ, London, England

[11] Erasmus MC Univ Med Ctr Rotterdam, Rotterdam, Netherlands

[12] Imaging Inst Southern Switzerland IIMSI, Lugano, Switzerland

[13] IOSI Oncol Inst Southern Switzerland, Lodrino, Switzerland

[14] Oncol Inst Southern Switzerland, Bellinzona, Switzerland

[15] Semmelweis Egyet, Budapest, Hungary

[16] Semmelweis Univ, Dept Nucl Med, Med Imaging Ctr, Budapest, Hungary

[17] Amsterdam UMC Radiol & Nucl Med, Canc Ctr Amsterdam, Amsterdam, Netherlands

[18] Vrije Univ Amsterdam, Amsterdam UMC, Dept Radiol & Nucl, Amsterdam, Netherlands

[19] Canc Ctr Amsterdam, Imaging, Amsterdam, Netherlands

[20] Canc Ctr Amsterdam, Amsterdam, Netherlands

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-190277

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] Interim PET and DLBCL Treatment
不详
JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (03) : 25N - 25N
[2] High-risk DLBCL: interim PET? Not yet
Hertzberg, Mark
BLOOD, 2017, 130 (11) : 1277 - 1278
[3] ΔSUVmax for interim PET in DLBCL: old is new
Meignan, Michel
Gallamini, Andrea
BLOOD, 2020, 135 (25) : 2202 - 2203
[4] IS INTERIM PET USEFUL IN PLANNING TREATMENT FOR DLBCL?
Haioun, C.
ANNALS OF ONCOLOGY, 2011, 22 : 130 - 130
[5] Prognostic evaluation of interim PET negative DLBCL patients: Can baseline and interim PET imaging with clinical indicators offer additional value?
Chen, Xi
Sun, Xun
Zhang, Yongxue
An, Rui
Lan, Xiaoli
JOURNAL OF NUCLEAR MEDICINE, 2024, 65
[6] QUANTITATIVE INTERIM PET IS MORE ACCURATE THAN QUALITATIVE ASSESSMENT IN PREDICTING OUTCOME IN DLBCL
Elstrom, R. L.
Martin, P.
Solnes, L.
Furman, R. R.
Ruan, J.
Novruzov, F.
Coleman, M.
Leonard, J. P.
Osborne, J.
ANNALS OF ONCOLOGY, 2011, 22 : 157 - 157
[7] INTERIM PET POSITIVITY IN HODGKIN LYMPHOMA: CLINICAL FEATURES AND OUTCOMES
Gaudio, F.
Perrone, T.
Sindaco, P.
Laddaga, F. E.
Pasciolla, C.
Franco, A.
Asabella, A. N.
Pedote, P.
Specchia, G.
HAEMATOLOGICA, 2016, 101 : 42 - 43
[8] Quantification of Lymphoma using FDG PET Heterogeneity Features for Improved Prediction of Clinical Outcome
Rahmim, Arman
Ashrafinia, Saeed
Rowe, Steven
Schmidtlein, Charles
Vendelbo, Mikkel
El-Galaly, Tarec
Gormsen, Lars
Munk, Ole
JOURNAL OF NUCLEAR MEDICINE, 2018, 59
[9] INTERIM FDG-PET SCANNING FOR DLBCL SHOULD REMAIN INVESTIGATIONAL
Moskowitz, C. H.
ANNALS OF ONCOLOGY, 2011, 22 : 130 - 130
[10] Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients
Eertink, J. J.
Burggraaff, C. N.
Heymans, M. W.
Duehrsen, U.
Huettmann, A.
Schmitz, C.
Mueller, S.
Lugtenburg, P. J.
Barrington, S. F.
Mikhaeel, N. G.
Carr, R.
Czibor, S.
Gyoerke, T.
Ceriani, L.
Zucca, E.
Hutchings, M.
Kostakoglu, L.
Loft, A.
Fanti, S.
Wiegers, S. E.
Pieplenbosch, S.
Boellaard, R.
Hoekstra, O. S.
Zijlstra, J. M.
de Vet, H. C. W.
BLOOD ADVANCES, 2021, 5 (09) : 2375 - 2384

← 1 2 3 4 5 →